Obesity in the Elderly and Its Management

Definition. As per WHO, malnutrition includes excesses as well as deficiencies — obesity is a form of malnutrition. Conventionally defined as BMI ≥30 kg/m²; overweight = 25–29.9 kg/m². The prevalence of obesity among older persons is growing.

Body composition changes with ageing make BMI unreliable. Fat mass increases and redistributes centrally (visceral and ectopic — liver, muscle), while lean mass falls by up to 3 kg per decade after age 50. Because BMI cannot separate fat from fat-free mass, and kyphosis makes height measurement unreliable, change in weight is preferred to change in BMI in older adults.

The “obesity paradox.” A meta-analysis showed BMI 25–29.9 is not associated with a significantly increased mortality risk in older adults, while BMI ≥30 carries only a modest (~10%) increase, irrespective of sex, disease status or smoking. Proposed explanations: selective survival, cohort effects, a ceiling effect of mortality rates, and the limitations of BMI as a measure of body composition. In the US NHIS 1997–98, only 47.2% of those ≥75 were overweight versus 63.5% of those aged 45–64.

Central adiposity is the better risk marker. A higher waist-to-hip ratio was associated with increased mortality independent of smoking, alcohol and oestrogen use in 31,702 Iowan women followed 11–12 years. But WHR is hard to interpret in old age — narrow hips may reflect gluteal muscle wasting rather than low fat. The literature on BMI, WHR and waist circumference in elders remains inconsistent; waist circumference is nonetheless simple, inexpensive and captures both effects.

Sarcopenic obesity. Defined as the coexistence of diminished lean mass and increased fat mass. At a BMI cut-off of ~27 kg/m², 14% of men <70 and 29% of men >80 were sarcopenic-obese, and 5% of women <70 and 8% of women >80. It is the phenotype that carries the worst functional prognosis.

Visceral fat drives the metabolic syndrome. While generalised obesity is linked to excess mortality, CVD, osteoarthritis, mobility impairment and disability, it is predominantly excess visceral fat that produces dyslipidaemia, raised fibrinogen, hyperinsulinaemia, glucose intolerance or diabetes, vascular insulin resistance, hypertension and cardiovascular disease. All components of the metabolic syndrome are prevalent in older populations.

Adverse consequences in older adults. Metabolic/cardiovascular: hypertension, type 2 diabetes, dyslipidaemia, coronary artery disease. Musculoskeletal: high BMI increases knee osteoarthritis risk; mechanical burden on ageing joints. Respiratory: pulmonary function abnormalities, obesity-hypoventilation syndrome, obstructive sleep apnoea. Genitourinary/GI: urinary incontinence rises with BMI; obesity is associated with faecal incontinence in women. Oncological: breast, colon, pancreas, renal, bladder and prostate cancer. Functional: markedly reduced self-reported mobility, exacerbation of age-related functional decline, frailty, higher rate of nursing-home admission, and impaired quality of life.

Beneficial effects of obesity in old age. Increased bone mineral density with reduced osteoporosis and hip fracture in older men and women, plus greater nutritional reserve during acute illness. This is why obesity in older adults is a target for function and quality of life, not primarily for mortality.

Clinical assessment. Measure weight, height (or knee-height estimate), BMI, waist circumference and waist-to-hip ratio; use DXA, BIA or CT for body composition where available. Assess muscle function — handgrip strength, gait speed, chair rise, SPPB — to detect sarcopenic obesity. Screen for metabolic syndrome components, OSA, osteoarthritis, incontinence and depression; review drugs causing weight gain (insulin, sulphonylureas, steroids, antipsychotics); and establish the patient’s function, goals and life expectancy before setting a weight target.

The cardinal principle. Weight-loss therapy that minimises muscle and bone loss is recommended only for older persons who are obese AND have functional impairments or metabolic complications that can benefit from weight loss. In sarcopenic obesity, prevention of further muscle loss takes priority over weight Nutrition in the Elderly — MD Geriatric Medicine Revision Page 19 of 25 reduction.

Lifestyle change is the primary approach, with modest goals. A modest reduction in energy intake of 500– 700 kcal/day is recommended. Note that short-term caloric restriction improves blood pressure, cholesterol and metabolic rate only when the reduction is at least 20%.

Exercise is not optional. Regular physical activity is particularly important in obese older persons to improve physical function and help preserve muscle and bone mass. Exercise plus diet is the most effective non-surgical treatment for obesity and is uniformly advocated by international consensus panels. Adding exercise to diet gives greater weight loss, preservation of fat-free mass and resting metabolic rate, improved fitness, correction of visceral-obesity-related metabolic abnormalities, and better long-term dietary adherence.

Choosing the exercise modality. Aerobic training may be somewhat better for reducing abdominal fat, and most robust studies used moderate- to high-intensity aerobic exercise; there is no evidence that low-intensity exercise reduces abdominal fat. Energy restriction causes significant loss of muscle and bone; adding resistance training prevents these adverse body-composition changes, whereas aerobic exercise alone does not. Resistance training is more suitable for older obese people with cardiovascular disease, arthritis, osteoporosis or mobility disorders who cannot tolerate sustained aerobic work. Combined aerobic plus resistance training is superior to aerobic alone for trunk fat in older men.

Small weight loss, large visceral benefit. Preferential visceral fat mobilisation means that a loss of only ~5% of total body weight or fat mass may produce a 25% or greater reduction in visceral fat, with important metabolic implications for insulin resistance.

Many benefits are independent of weight loss. Blood pressure can be lowered by dietary change (DASH) without weight loss, and this effect persists for 3–5 years despite weight regain; coronary prevention effects and improvements in physical function are also obtainable without weight loss. The improvement comes from lifestyle change, not necessarily from the weight falling.

Evidence from major trials. In Look AHEAD, intensive lifestyle intervention in diabetes produced sustained weight loss, improved fitness and better cardiovascular risk factors, but no reduction in cardiovascular events, no difference in objective neuropathy, and marginally greater cognitive decline in obese subjects at five years. In older adults randomised to caloric restriction versus exercise, caloric restriction produced greater weight loss but also greater loss of lean mass, with no long-term difference in physical performance between the two.

Protect nutrition during weight loss. Provide protein 1.0–1.5 g/kg/day, adequate calcium (1000–1200 mg) and vitamin D (800 IU), and avoid intakes below ~1500 kcal/day, since low energy intake almost guarantees micronutrient inadequacy. Emphasise nutrient-dense foods.

Avoid weight cycling. Repeated attempts at sustained weight loss cause loss of lean tissue (muscle and bone) and a fall in metabolic rate, worsening the energy-balance equation and making long-term dietary management progressively harder.

Pharmacotherapy. The available data are insufficient to determine the efficacy and safety of pharmacotherapy for obesity in older persons. In obese older adults with type 2 diabetes, weight-loss diets are central; metformin may act as an appetite suppressant and acarbose reduces carbohydrate absorption. Note that insulin itself causes significant weight gain, aggravating the underlying problem.

Bariatric surgery and monitoring. Bariatric surgery is the most effective weight-loss therapy, but in older patients perioperative morbidity and mortality are greater, while relative weight loss and improvement in obesity-related complications are lower than in younger patients. It should therefore be reserved for a select group of older subjects with disabling obesity that can be ameliorated by weight loss and who meet standard criteria. Throughout follow-up, distinguish intentional from unintentional weight loss — in SHEP, the excess mortality associated with weight loss was present even in the heaviest subjects (BMI ≥31) and was independent of baseline weight.

Obesity has been formally redefined — clinical vs preclinical. The Lancet Diabetes & Endocrinology Commission defines preclinical obesity as excess adiposity with preserved organ function and generally increased future risk, and clinical obesity as a chronic systemic illness with objective signs or symptoms of altered organ function or impaired ability to conduct daily activities directly caused by excess adiposity. Confirmation of excess adiposity requires either direct body fat measurement (DXA or bioimpedance), or at least one anthropometric criterion in addition to BMI, or at least two anthropometric criteria regardless of BMI — using waist circumference, waist-to-hip ratio or waist-to-height ratio with age-, sex- and ethnicity-appropriate cut-offs. Diagnosis of clinical obesity requires at Nutrition in the Elderly — MD Geriatric Medicine Revision Page 20 of 25 least one of 18 specified obesity-related conditions in adults. This directly addresses the textbook’s complaint that BMI performs poorly in older adults. (Rubino F, et al. Lancet Diabetes Endocrinol. 2025;13:221–262.)

India has its own revised definition — highly examinable. In Stage 1 obesity, individuals have increased adiposity (BMI >23 kg/m²) without discernible effects on organ function or daily activities. Stage 2 obesity denotes a more advanced state with generalised and abdominal adiposity affecting physical and organ function and causing functional limitation, requiring BMI >23 kg/m² plus abdominal adiposity (excess waist circumference or waist-to-height ratio) plus either a mechanical condition such as knee arthritis due to excess weight, or an obesity-associated disease such as type 2 diabetes. This is “obesity with consequences” and mandates more intensive management. (Misra A, Vikram NK, Ghosh A, et al. Diabetes Metab Syndr. 2025;19:102989.)

EASO’s parallel framework. The EASO report retains BMI ≥30 kg/m² but adds BMI >25 kg/m² with a waist-to-height ratio >0.5, with both criteria requiring evidence of medical, functional or mental limitation. (EASO framework, 2024.)

Sarcopenic obesity now has consensus diagnostic criteria — but they need validation. In 2022 ESPEN and EASO issued the first global consensus on diagnostic methods for sarcopenic obesity; applied for the first time in free-living older adults, the algorithm gave a prevalence of 9% and was 100% sensitive for diagnosis, with insulin resistance and an altered ghrelin profile emerging as risk factors. A Western Chinese community validation found a prevalence of 13.2% by ESPEN/EASO criteria, rising with age and BMI and associated with falls. However, the ESPEN/EASO consensus showed poor diagnostic agreement with other commonly used sarcopenic-obesity definitions in a 4,155-participant Chinese cohort. (Donini LM, et al. Clin Nutr / Obes Facts. 2022; Clin Nutr. 2023; Arch Gerontol Geriatr. 2024;127:105557; Front Endocrinol. 2024.)

GLP-1 receptor agonists work as well in the elderly. A post hoc analysis of the SURMOUNT and SUMMIT phase 3 trials in adults ≥65 years found that all tests for treatment-by-age-group interaction were non-significant for percent body weight change, waist circumference, systolic blood pressure and HbA1c, indicating comparable efficacy in older and younger participants. Head-to-head, SURMOUNT-5 demonstrated superior efficacy of tirzepatide over semaglutide for percentage weight change and for weight-reduction targets of ≥10%, ≥15%, ≥20% and ≥25% at 72 weeks, with greater improvements in blood pressure, HbA1c, fasting insulin, triglycerides and HDL. (Alfaris N, et al. Diabetes Obes Metab. 2026; Aronne LJ, et al. N Engl J Med. 2025;393:26–36.)

But the geriatric caveats are serious. GLP-1 RAs effectively induce weight loss, but concomitant muscle mass loss is common, raising concerns about sarcopenia and sarcopenic obesity in older adults. A meta-analysis of eight RCTs found participants regained 9.69 kg over 48–52 weeks after stopping semaglutide or tirzepatide. Handgrip strength appears statistically preserved in short-to-mid-term trials, but longitudinal and retrospective research in older adults with type 2 diabetes has reported reduced handgrip strength and accelerated sarcopenia with prolonged semaglutide use. Practical rule: never prescribe a GLP-1 RA to an older adult without concurrent adequate protein intake and resistance training. (Curr Nutr Rep. 2026; Maturitas. 2025.)

ESPEN sets the threshold for intervention. Weight loss in old age should be considered only in cases of obesity with associated health problems, and should be achieved by moderate energy reduction in combination with exercise. Dietary restrictions should generally be avoided in older persons. (Volkert D, et al. Clin Nutr. 2022;41:958–989.)

India’s double burden in the elderly. In LASI, about 25% of males and 37% of females aged 45–59 are overweight or obese, while among those aged 60 and above 28% of males and 25% of females are underweight; the urban population is more than twice as likely to be overweight and less likely to be underweight. Age-appropriate Indian BMI cut-offs derived from LASI differ substantially from WHO values in those aged 60 and above. (Khan J, et al. Sci Rep. 2023;13:12820; Singh A, Chattopadhyay A. Sci Rep. 2024;14:15200.)

Enteric (malabsorption) · Eating problems (unable to self-feed) · Low-salt / low-cholesterol diets · Social isolation, Stones Ten Concepts That Earn Marks in Any Nutrition Question Malnutrition is a geriatric syndrome — multifactorial, poor outcomes, needs CGA. Three-step approach: SCREEN (MNA-SF) → DIAGNOSE (GLIM) → GRADE (CRP). Starvation responds to refeeding; cachexia does not — CRP is the bedside discriminator. Serial weight beats BMI — kyphosis makes height unreliable. Albumin is an inflammatory marker, not a nutritional one — excluded from GLIM. Anaemia is one of the earliest manifestations of PEM. ONS need the right dose and duration — ≥400 kcal/day for ≥35 days. Exercise is the stimulus, nutrition is permissive — neither works alone in sarcopenia. PEG in advanced dementia neither prolongs survival nor prevents aspiration. Obesity in the elderly is a target for function, not mortality — and in sarcopenic obesity, muscle comes before weight. Three Places Where the Textbook Is Now Outdated — Know These Cold Megestrol acetate: the textbook calls it the best-studied orexigenic; AGS Beers 2023 says AVOID. Albumin: the textbook calls it a practical indicator of malnutrition; it is now an inflammatory/prognostic marker excluded from GLIM. Obesity pharmacotherapy: the textbook says data are insufficient in older persons; GLP-1/GIP agonists now have positive ≥65-year post hoc data, tempered by lean-mass loss and weight regain. End of document · Textbook content from Pathy’s 6th ed. and Essentials of Clinical Geriatrics 7th ed. · Updates current to August 2026 Nutrition in the Elderly — MD Geriatric Medicine Revision Page 25 of 25